Leukaemia Trial, Recruiting (NCT06459024)

Leukaemia Trial, Recruiting NCT06459024 Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT06459024 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with Acute Myeloid Leukaemia (AML) according to specific international diagnostic guidelines (WHO 2022 or ICC 2022)
People whose AML treatment has not worked, including cases where the disease has come back, did not respond to treatment, has gotten worse, or where testing has detected remaining cancer cells at a very low level (confirm with trial site)
People who are willing and able to give their formal agreement to take part, or who have a legal representative who can do this on their behalf

Who may not be able to join:

People who are already taking part in another clinical trial may still be considered for this trial, unless the rules of that other trial specifically say otherwise (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Giovanni Martinelli, MD, Prof, University of Bologna

Phone: +39 0543 739100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06459024

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

Trial contact: +39 0543 739100

More information: https://clinicaltrials.gov/study/NCT06459024

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with Acute Myeloid Leukaemia (AML) according to specific international diagnostic guidelines (WHO 2022 or ICC 2022)
People whose AML treatment has not worked, including cases where the disease has come back, did not respond to treatment, has gotten worse, or where testing has detected remaining cancer cells at a very low level (confirm with trial site)
People who are willing and able to give their formal agreement to take part, or who have a legal representative who can do this on their behalf

Who may not be able to join:

People who are already taking part in another clinical trial may still be considered for this trial, unless the rules of that other trial specifically say otherwise (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Registry

ClinicalTrials.gov

Start date

28 June 2024

Est. completion

1 July 2032

Where this trial is recruiting

🇩🇪 Germany 🇮🇹 Italy 🇱🇹 Lithuania 🇵🇱 Poland 🇷🇴 Romania 🇪🇸 Spain

Primary endpoints

The primary endpoint is to determine the overall survival of R/R AML patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov